US › Healthcare

Biocardia Inc (BCDA)

US · Healthcare · Biotechnology

$0.91+9.50%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-2.3M
Profit YoY
+16.7%
EPS
$-0.21
EPS estimate
$-0.17

EPS came in at -0.21 against a street estimate of -0.17 — a miss of 23.5%.

Key statistics

Market cap
$12.4M
Forward P/E
0.0
P/B
12.35
Book value
$-0.10
EPS (TTM)
$-0.85
52-week high
$2.29
52-week low
$0.75
50-day MA
$0.94
200-day MA
$1.18
Beta
0.49

Analyst view

Analysts rate Biocardia Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $15.50.

Shareholding

Insiders
23.50%
Institutions
5.49%

Largest institutional holders

FundStake
Vanguard Group Inc0.91%
CM Management, LLC0.87%
Vanguard Capital Management, LLC0.84%
Geode Capital Management, LLC0.63%
Vanguard Fiduciary Trust Co0.45%
Citadel Advisors Llc0.43%
Susquehanna International Group, LLP0.26%
Pingora Partners LLC0.24%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Biocardia Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.